STAT5 has been shown to be constitutively activated in lymphoid, myeloid, and erythroid leukemias [27–29], suggesting that ART may block oncogenesis through suppression of tyrosyl phosphorylation of STAT5. This evidence concerns the gene STAT5B and leukemia.